CREDENCE: A silver lining in the dark cloud of diabetic nephropathy

[...]SGLT2 inhibitors have a strong effect in reducing the risk of deteriorating heart failure, which is closely associated with advanced diabetic nephropathy. A recent study of patients with heart failure and a reduced ejection fraction showed that the risk of deteriorating heart failure or death f...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of diabetes investigation Ročník 11; číslo 3; s. 527 - 529
Hlavní autoři: Hanai, Ko, Babazono, Tetsuya
Médium: Journal Article
Jazyk:angličtina
Vydáno: Japan John Wiley & Sons, Inc 01.05.2020
John Wiley and Sons Inc
Wiley
Témata:
Antidiabetics
Blood pressure
Canagliflozin - therapeutic use
Cardiovascular disease
Clinical trials
Commentaries
Confidence intervals
Congestive heart failure
Diabetes
Diabetes mellitus
Diabetic Nephropathies - diagnosis
Diabetic Nephropathies - drug therapy
Diabetic Nephropathies - epidemiology
Diabetic nephropathy
Enzymes
Glucose
Heart failure
Humans
Kidney diseases
Kidney Failure, Chronic - diagnosis
Kidney Failure, Chronic - epidemiology
Kidney Failure, Chronic - prevention & control
Nephropathy
Peptides
Randomized Controlled Trials as Topic - methods
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
ISSN:2040-1116, 2040-1124, 2040-1124
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:[...]SGLT2 inhibitors have a strong effect in reducing the risk of deteriorating heart failure, which is closely associated with advanced diabetic nephropathy. A recent study of patients with heart failure and a reduced ejection fraction showed that the risk of deteriorating heart failure or death from cardiovascular causes was lower in the dapagliflozin group than in the placebo group, regardless of the presence of diabetes . [...]the kidney‐protective effects observed in the CREDENCE study might have been noted because of the interruption of the vicious circle involving diabetic nephropathy and heart failure . [...]the CREDENCE study has provided evidence that canagliflozin administration is a beneficial therapy that delays kidney disease progression in patients with advanced diabetic nephropathy.
Bibliografie:SourceType-Scholarly Journals-1
ObjectType-Commentary-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2040-1116
2040-1124
2040-1124
DOI:10.1111/jdi.13175